Trial Profile

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Laromestrocel (Primary)
Indications Hypoplastic left heart syndrome
Focus Registrational; Therapeutic Use
Acronyms ELPIS II; ELPISII
Sponsors Longeveron

Most Recent Events

24 Jun 2025 According to a Longeveron media release, enrollment has been completed in this study, topline results being expected in Q3 2026, after the final follow-up at 12-months. This trial had enrolled 2 additional patients beyond target enrollment.
24 Jun 2025 According to a Longeveron media release, status changed from recruiting to active, no longer recruiting.
19 Jun 2025 Planned number of patients changed from 38 to 40.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com